📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Vaishali Pharma Shareholders Approve Preferential Issue of Equity Shares
Vaishali Pharma Limited has received shareholder approval through a postal ballot for the issuance and allotment of equity shares on a preferential basis. The special resolution was passed with an overwhelming majority, with 99.99% of the votes cast in favor by participating public shareholders. Promoters and the promoter group abstained from voting as they were interested parties in the resolution. This approval clears the path for the company to raise capital, which is typically used for expansion or strengthening the balance sheet.
Key Highlights
Special Resolution for issuing equity shares on a preferential basis was approved by shareholders.
The resolution received 99.9909% votes in favor from the public non-institutional category.
A total of 25,415,321 votes were polled during the postal ballot process.
Promoters and promoter group members abstained from voting due to their interest in the resolution.
The record date for determining eligibility for the postal ballot was February 6, 2026.
💼 Action for Investors
Investors should monitor upcoming disclosures regarding the specific allotment price and the list of allottees to evaluate the impact of equity dilution. The successful approval indicates strong shareholder support for the company's fundraising and growth plans.
Simbhaoli Sugars Reports Adverse Auditor Opinion on FY25 Results Amid Insolvency Proceedings
Simbhaoli Sugars' Interim Resolution Professional (IRP) has recorded the FY25 consolidated financial results, which have received an 'Adverse Opinion' from statutory auditors. The auditors cited significant 'Going Concern' uncertainties, including a year-long turbine breakdown at its power subsidiary and lack of financial support. Major financial discrepancies were noted, such as ₹1,116.19 Lakhs in disputed receivables and ₹462.57 Lakhs in unprovided doubtful debts at subsidiaries. The company remains under the Insolvency and Bankruptcy Code (IBC) with a critical NCLAT hearing scheduled for March 24, 2026.
Key Highlights
Statutory auditors issued an 'Adverse Opinion' on the FY25 consolidated financial results due to pervasive accounting issues.
Subsidiary SPPL faces 'Going Concern' doubts following a year-long turbine failure and ₹1,116.19 Lakhs in disputed receivables.
Subsidiary ICCPL failed to provide for ₹462.57 Lakhs in disputed unbilled revenue and ₹209.43 Lakhs in receivables overdue for 3+ years.
The company is currently under Corporate Insolvency Resolution Process (CIRP) with management controlled by an IRP.
NCLAT has stayed further insolvency steps until the next hearing on March 24, 2026, to allow for settlement proposals.
💼 Action for Investors
Investors should exercise extreme caution as the adverse audit opinion and ongoing insolvency proceedings suggest a high risk of total capital loss. The stock is highly speculative given the significant doubts regarding the company's ability to continue as a going concern.
Simbhaoli Sugars Receives Adverse Auditor Opinion on FY25 Results Amid IBC Proceedings
Simbhaoli Sugars' auditors have issued an adverse opinion on the consolidated financial results for the year ended March 31, 2025, indicating that the statements do not provide a true and fair view. The company is currently under the Insolvency and Bankruptcy Code (IBC) process, with an Interim Resolution Professional managing operations while NCLAT proceedings are ongoing. Significant financial irregularities were noted in subsidiaries, including a disclaimer of opinion for the power unit due to turbine failures and disputed receivables of ₹1,116.19 lakhs. The consultancy arm also faces adverse findings regarding ₹462.57 lakhs in unbilled revenue and long-overdue receivables.
Key Highlights
Auditors issued an 'Adverse Opinion' on consolidated FY25 results, citing pervasive accounting and valuation issues.
The company is under the IBC process; NCLAT has stayed further insolvency steps but allowed the IRP to manage operations until March 24, 2026.
Subsidiary SPPL faces a 'Disclaimer of Opinion' due to a non-working turbine and a ₹1,116.19 lakh disputed receivable from the parent company.
Subsidiary ICCPL failed to provide for ₹462.57 lakhs in disputed unbilled revenue and ₹209.43 lakhs in receivables overdue for more than three years.
Significant doubts remain regarding the 'Going Concern' status of the group due to persistent losses and current liabilities exceeding current assets.
💼 Action for Investors
Investors should exercise extreme caution as the adverse auditor opinion and ongoing insolvency proceedings indicate high risk and unreliable financial reporting. The next critical milestone is the NCLAT hearing scheduled for March 24, 2026.
HAL Reaffirmed CARE AAA; Stable Rating with ₹2.59 Lakh Crore Order Book
CARE Ratings has reaffirmed HAL's highest 'AAA' rating for its ₹6,050 crore bank facilities, reflecting its strategic importance to India's defense sector. The company's order book has nearly doubled to ₹258,942 crore as of September 2025, providing revenue visibility for the next 7-8 years. HAL maintains an exceptionally strong financial profile with ₹43,465 crore in free cash and zero reliance on external debt. Profitability remains healthy with a 29.19% PBILDT margin in FY25 and a future order pipeline estimated up to ₹1 lakh crore.
Key Highlights
CARE reaffirmed 'CARE AAA; Stable / CARE A1+' ratings for ₹6,050 crore bank facilities.
Order book surged to ₹258,942 crore as of Sept 30, 2025, compared to ₹133,238 crore in Dec 2024.
Strong liquidity position with free cash and equivalents of ₹43,465 crore and customer advances of ₹52,219 crore.
FY25 Total Operating Income stood at ₹30,146 crore with a healthy PBILDT margin of 29.19%.
Future order pipeline estimated between ₹60,000 crore and ₹1,00,000 crore expected within 1-2 years.
💼 Action for Investors
The rating reaffirmation and massive order book growth reinforce HAL's dominant position in the defense sector. Investors should remain positive given the company's zero-debt status and multi-year revenue visibility.
Shalby Launches Advanced Oncology and Radiotherapy Department at Surat Hospital
Shalby Limited has inaugurated a comprehensive Oncology Department at its Surat multi-specialty hospital. The new facility includes advanced radiotherapy services, enabling the hospital to provide integrated cancer care across medical, surgical, and radiation oncology. This expansion targets the South Gujarat region, aiming to provide specialized diagnosis and treatment under one roof. The addition of high-margin oncology services is expected to enhance the hospital's service mix and potentially improve its Average Revenue Per Occupied Bed (ARPOB).
Key Highlights
Inauguration of a dedicated Oncology Department at Shalby Multi-Specialty Hospital, Surat
Introduction of advanced Radiotherapy facilities for comprehensive cancer treatment
Integrated care model featuring medical, radiation, and surgical oncology teams
Strategic expansion to capture demand for specialized cancer care in the South Gujarat region
💼 Action for Investors
Investors should view this as a positive operational development that could boost high-margin revenue for the Surat unit. Monitor future quarterly results for improvements in ARPOB and occupancy driven by these specialized services.
Shalby Subsidiary PK Healthcare Receives NABH Accreditation Valid Until 2030
Shalby Limited's subsidiary, PK Healthcare Private Limited (Shalby International Hospitals) located in Gurugram, has been granted accreditation by the National Accreditation Board for Hospitals & Healthcare Providers (NABH). The accreditation follows the 6th Edition Standards, which focus on patient safety, clinical governance, and risk management. This certification is valid for a period of four years, extending until 2030. Such accreditations are critical for healthcare providers to maintain quality benchmarks and attract corporate and insurance-linked patients.
Key Highlights
PK Healthcare Pvt Ltd (Gurugram) granted NABH accreditation under the rigorous 6th Edition Standards.
The accreditation is valid for a long-term duration until the year 2030.
Framework emphasizes patient safety protocols, clinical governance, and continuous quality improvement.
Accreditation strengthens the hospital's position in evidence-based clinical care and infection control.
💼 Action for Investors
Investors should view this as a positive operational milestone that validates the quality of healthcare services at Shalby's Gurugram facility. This accreditation is likely to improve the hospital's reputation and operational efficiency, supporting long-term revenue growth.
Marshall Machines 5th CoC Meeting: Resolution Plan De-sealed and Transaction Audit Discussed
Marshall Machines Limited is currently undergoing the Corporate Insolvency Resolution Process (CIRP), with the 5th Committee of Creditors (CoC) meeting held on February 26, 2026. A significant development is the de-sealing of a Resolution Plan submitted by a prospective applicant, indicating progress toward a potential turnaround. The CoC also discussed the Transaction Audit Report and the methodology for asset valuation. E-voting on several items, including the non-disclosure of fair value and ratification of costs, is scheduled to conclude on March 5, 2026.
Key Highlights
5th CoC meeting held on February 26, 2026, to progress the insolvency resolution process.
De-sealing of a Resolution Plan submitted by a Prospective Resolution Applicant (PRA) was a key agenda item.
Discussion held on the Transaction Audit Report and the methodology for valuing the Corporate Debtor's assets.
E-voting for agenda items, including CIRP cost ratification, runs from February 28 to March 5, 2026.
Proposal to approve non-disclosure of fair value in the Information Memorandum as per new IBBI regulations.
💼 Action for Investors
Investors should remain extremely cautious as the company is in insolvency, which typically results in significant equity dilution or total loss. Monitor the outcome of the resolution plan evaluation to see if the company can successfully emerge from CIRP.
Vaishali Pharma to Acquire 51.02% of Kesar Pharma; Preferential Issue at Rs 20 Per Share
Vaishali Pharma has issued a corrigendum to its postal ballot notice regarding the acquisition of a 51.02% stake in Kesar Pharma Limited. The deal involves a preferential issue of shares at Rs 20 each, which is significantly higher than the SEBI-mandated floor price of Rs 09.46. The floor price was derived from the 90-day volume-weighted average price (VWAP) as per regulatory requirements. Shareholders have until March 15, 2026, to cast or modify their votes based on these updated disclosures.
Key Highlights
Proposed acquisition of a 51.02% majority stake in Kesar Pharma Limited
Preferential shares to be issued at Rs 20 per share, a 111% premium over the floor price of Rs 09.46
Floor price based on 90-day VWAP of Rs 09.46 and 10-day VWAP of Rs 08.02
Relevant date for the transaction pricing is February 13, 2026
E-voting facility for shareholders is open until 05:00 PM on March 15, 2026
💼 Action for Investors
Investors should monitor the successful integration of Kesar Pharma as it represents a significant majority acquisition. The high issue price relative to the floor price is a positive signal regarding the company's internal valuation.
Shalby Increases Stake in Subsidiary PK Healthcare to 91.13% via Rs 59.6 Cr Rights Issue
Shalby Limited has increased its stake in its subsidiary, PK Healthcare Private Limited (PKHPL), from 87.26% to 91.13%. The company invested approximately Rs 59.60 crore by subscribing to 5.96 crore equity shares at a price of Rs 10 per share through a rights issue. The capital infusion will be utilized by PKHPL for debt repayment and working capital requirements. PKHPL, which focuses on the Delhi/NCR healthcare market, reported a turnover of Rs 91.19 crore in FY 2024-25.
Key Highlights
Acquired 5,96,01,950 equity shares of PK Healthcare at Rs 10 per share
Total investment amount stands at Rs 59,60,19,500
Shalby's shareholding in PKHPL increased from 87.26% to 91.13%
Funds will be used by the subsidiary for debt repayment and working capital
PKHPL's turnover grew from Rs 67.36 crore in FY23 to Rs 91.19 crore in FY25
💼 Action for Investors
This move consolidates control and helps deleverage a key subsidiary in the high-growth Delhi/NCR region. Investors should monitor if this capital infusion leads to improved consolidated margins for Shalby in the coming quarters.
Chalet Hotels to Invest ₹633 Crore for New 330-Room Luxury Hotel in Hyderabad
Chalet Hotels has approved the development of a new luxury hotel in Madhapur, Hyderabad, featuring approximately 330 rooms and 36,255 sq. ft. of retail space. The project involves a total investment of approximately Rs. 6,328 million, which will be funded through a combination of internal accruals and debt. This facility will be the company's third hotel in the Hyderabad market and is expected to be operational by FY2029. The development will be part of a building premises obtained on a warm shell lease, aligning with the company's asset-light expansion strategy.
Key Highlights
Proposed development of a ~330-room luxury hotel in Madhapur, Hyderabad
Includes ~36,255 sq. ft. of commercial and retail space within the premises
Total estimated investment of ~Rs. 6,328 million including security deposits
Project completion targeted for FY2029, financed via debt and internal accruals
Marks the company's third hotel property in the Hyderabad region
💼 Action for Investors
Investors should view this as a long-term growth driver that strengthens Chalet's footprint in a key business hub. Monitor the company's debt-to-equity ratio as it executes this capital-intensive project over the next three years.
Chalet Hotels to invest ₹633 Cr for new 330-room luxury hotel in Hyderabad
Chalet Hotels has approved the development of a new luxury hotel project in the Madhapur area of Hyderabad, marking its third property in the city. The project will feature approximately 330 rooms and 36,255 sq. ft. of commercial and retail space. The company has earmarked an investment of Rs. 6,328 million (approx. ₹633 crore) for this development, which will be funded through a mix of internal accruals and debt. The project is expected to be completed and operational by FY2029.
Key Highlights
Total investment outlay of approximately Rs. 6,328 million including security deposits
Addition of ~330 luxury rooms and ~36,255 sq. ft. of commercial/retail space
Project to be developed on a warm shell lease basis in the Madhapur IT hub
Targeted completion and operationalization by the end of FY2029
Funding to be managed through a combination of debt and internal accruals
💼 Action for Investors
Investors should look at this as a significant long-term capacity expansion in a high-demand micro-market. While the gestation period is long (FY2029), it strengthens the company's portfolio in the premium hospitality segment.
Marshall Machines Updates on CIRP; CoC Approves 90-Day Extension for Insolvency Process
Marshall Machines Limited is currently undergoing the Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code. Recent Committee of Creditors (CoC) meetings have finalized the issuance of Form G to invite potential resolution applicants and established an evaluation matrix for bids. Crucially, the CoC has approved a 90-day extension for the completion of the CIRP to allow more time for the submission and vetting of resolution plans. The company has also replaced its Interim Resolution Professional with Mavent Restructuring Services LLP to lead the process.
Key Highlights
CoC approved the replacement of the IRP with Mavent Restructuring Service LLP as the Resolution Professional.
Issuance of Form G for Expression of Interest (EOI) to identify prospective resolution applicants has been initiated.
Approved filing an application for a 90-day extension to the statutory timeline for completing the CIRP.
Request for Resolution Plan (RFRP) and Evaluation Matrix for assessing potential bids have been finalized.
Ratified various administrative costs including fees for valuers, forensic auditors, and legal counsel.
💼 Action for Investors
Investors should remain highly cautious as equity shareholders typically face significant dilution or total loss of value during insolvency proceedings. Monitor the NCLT's approval of the extension and the quality of resolution plans submitted by prospective applicants.
Shalby Q3 FY26: Consolidated PAT Turns Positive at ₹1.3 Cr; MedTech Revenue Jumps 29% YoY
Shalby Limited reported a marginal 0.6% YoY decline in consolidated revenue to ₹279.4 crores for Q3 FY26, while consolidated PAT turned positive at ₹1.3 crores compared to a loss in the previous year. The core hospital business faced headwinds with a 2.6% revenue decline and lower occupancy of 44%, primarily due to ongoing negotiations with major insurance providers. Conversely, the MedTech segment showed strong momentum with 29% revenue growth and achieved EBITDA breakeven for the first time. The company maintains a stable balance sheet with a net debt of ₹408 crores and a low gearing ratio of 0.41x.
Key Highlights
Consolidated PAT improved to ₹1.3 crores from a loss of ₹3 crores in the same quarter last year.
MedTech segment revenue grew 29% YoY to ₹30.38 crores, with EBITDA turning positive at ₹0.7 million.
Hospital standalone revenue declined 2.6% YoY to ₹221 crores with occupancy dropping to 44% from 46%.
ARPOB (Average Revenue Per Occupied Bed) saw a marginal increase of 1.1% YoY to ₹43,171.
Shalby International (Gurgaon) reported revenue of ₹23.9 crores with 51% contribution from international patients.
💼 Action for Investors
Investors should monitor the recovery in hospital occupancy once insurance negotiations are finalized and track the scalability of the now-profitable MedTech division. The stock remains a watch as the company transitions its medical implant business from a turnaround to a growth phase.
Chalet Hotels Secures Stay from Karnataka HC on Rs 39.56 Cr Property Tax Notice
Chalet Hotels Limited has successfully obtained a stay order from the High Court of Karnataka against a property sale notice issued by the Greater Bengaluru Authority. The dispute involves alleged non-payment of property tax dues amounting to approximately Rs 39.56 crore, which includes interest, penalties, and cess. The notice pertained to the company's property located in Whitefield, Bengaluru. This legal intervention prevents the immediate sale of the asset until the next hearing date, providing temporary relief to the company.
Key Highlights
High Court of Karnataka granted a stay order on the 'Proclamation and Written Notice of Sale' of the Whitefield property.
The total disputed amount claimed by the Greater Bengaluru Authority is approximately Rs 39.56 crore.
The claim includes principal property tax, interest, penalties, and applicable cess.
The stay order remains effective until the next scheduled date of hearing in the Writ Petition filed by the company.
💼 Action for Investors
Investors should monitor the final court ruling as a negative outcome would require a cash outflow of Rs 39.56 crore. The current stay is a positive procedural development that protects the company's Bengaluru asset from immediate liquidation.
Vaishali Pharma to Issue 61.23 Lakh Shares for 33.24% Stake in Kesar Pharma
Vaishali Pharma Limited has issued a postal ballot notice to seek shareholder approval for a preferential allotment of 61.23 lakh equity shares. The shares are priced at Rs. 20 each, representing a total transaction value of approximately Rs. 12.25 crores. This is a non-cash transaction involving a share swap to acquire a 33.24% stake in Kesar Pharma Limited, an associate company. The e-voting period for shareholders is scheduled from February 14 to March 15, 2026.
Key Highlights
Preferential issue of up to 61,23,000 equity shares at an issue price of Rs. 20 per share
Total consideration of Rs. 12.25 crores to be settled via share swap (non-cash)
Acquisition of 21,52,575 shares in Kesar Pharma Limited, representing a 33.24% stake
Relevant date for floor price determination fixed as February 13, 2026
E-voting results to be announced on or before March 17, 2026
💼 Action for Investors
Investors should assess the strategic value of consolidating the stake in Kesar Pharma against the equity dilution caused by the new share issuance. Monitor the final approval and subsequent integration of Kesar Pharma's operations.
Shah Alloys Q3 Profit at ₹35.22 Cr Driven by ₹67.46 Cr Asset Sale; Main Plant Closed
Shah Alloys reported a net profit of ₹35.22 Crores for Q3 FY26, a turnaround from a loss of ₹15.26 Crores in the previous year, entirely due to exceptional gains of ₹67.46 Crores from asset and investment sales. Revenue from operations plummeted 80% YoY to ₹10.29 Crores as the company's primary Iron and Steel plant has been shut down since August 2025 due to technology obsolescence. Auditors have issued a qualified opinion, flagging material uncertainty regarding the company's status as a 'Going Concern' and noting the non-provision of ₹36.55 lakhs in bank interest. The company is currently exploring options for its future after liquidating significant plant machinery and its stake in SAL Steel Limited.
Key Highlights
Net Profit of ₹35.22 Crores in Q3 FY26 vs a Loss of ₹15.26 Crores in Q3 FY25, driven by one-time gains.
Exceptional items of ₹67.46 Crores include a ₹53.47 Crore gain from selling plant/machinery and a ₹13.98 Crore gain from SAL Steel share sale.
Revenue from operations fell sharply to ₹10.29 Crores from ₹51.90 Crores YoY following the closure of the Santej plant.
Auditors expressed inability to confirm 'Going Concern' status as the main manufacturing facility is no longer operational.
Qualified opinion issued for non-provision of ₹36.55 lakhs in interest on bank loans for the quarter.
💼 Action for Investors
Investors should treat the reported profit as a non-recurring event resulting from asset liquidation rather than operational strength. Given the plant closure and auditor warnings on 'Going Concern' status, the stock carries high risk and requires a cautious approach until a new business model is established.
Halder Venture Q3 Profit Falls YoY; Announces ₹30.16 Cr Acquisition of Inqube Technologies
Halder Venture Limited reported a standalone net profit of ₹2.17 crore for Q3 FY26, a sharp decline from ₹13.45 crore in the same quarter last year, though it showed sequential improvement from Q2. The company has approved a strategic acquisition of a 52% stake in Inqube Technologies for ₹30.16 crore to diversify into Agri-ERP and carbon credit markets. Operationally, the company has started packaging at its Haldia unit, capitalizing ₹22.45 crore. However, auditors have raised concerns regarding a pending ₹6.05 crore dividend from a foreign subsidiary that remains uncollected.
Key Highlights
Standalone Net Profit for Q3 FY26 at ₹2.17 crore, down 83.8% YoY from ₹13.45 crore.
Approved acquisition of 52% stake in Inqube Technologies Private Limited for ₹30.16 crores.
Revenue from operations fell to ₹73.63 crore in Q3 FY26 from ₹286.97 crore in Q3 FY25.
Capitalized ₹22.45 crore following the operationalization of packaging units at the Haldia Manufacturing Unit.
Auditors highlighted a potential impairment risk for ₹6.05 crore in dividend income receivable from a foreign subsidiary.
💼 Action for Investors
Investors should closely monitor the execution of the Inqube acquisition and the recovery of the ₹6.05 crore dividend from the foreign subsidiary. While the YoY earnings drop is concerning, the operationalization of the Haldia unit and the new tech-focused acquisition are key long-term growth drivers to track.
Halder Venture Fined ₹5.43 Lakh by BSE for Board Composition Non-Compliance
Halder Venture Limited has been penalized ₹5,42,800 by BSE for failing to comply with SEBI Regulation 17(1) regarding board composition during the September 2025 quarter. The company explained that the lapse occurred during the transition period following an amalgamation that made corporate governance norms applicable. Management confirmed that the company became fully compliant on November 14, 2025, and has since filed a waiver application with the exchange. The Board has reviewed the matter and advised the management to exercise abundant caution to ensure future regulatory adherence.
Key Highlights
BSE imposed a total fine of ₹5,42,800 (including ₹82,800 GST) for non-compliance with Regulation 17(1).
The company achieved full compliance with board composition requirements on November 14, 2025.
A waiver application for the levied fine was filed with BSE on December 1, 2025.
The regulatory lapse followed a Scheme of Amalgamation that became effective on January 1, 2025.
💼 Action for Investors
Investors should note the governance lapse but also recognize that the company has already rectified the board composition. Monitor the outcome of the waiver application and ensure no further regulatory delays occur in future filings.
Halder Venture to Acquire 52% Stake in Inqube Technologies for ₹30.16 Crores
Halder Venture Limited has approved the acquisition of a 52% controlling stake in Inqube Technologies Private Limited for ₹30.16 crores, aimed at integrating cloud-based Agri-ERP solutions and entering the carbon credits market. For the quarter ended December 31, 2025, the company reported standalone revenue of ₹73.63 crores and a net profit of ₹2.17 crores. The company also operationalized its Haldia packaging unit, capitalizing ₹22.45 crores in the process. However, auditors highlighted a pending dividend of ₹6.05 crores from a foreign subsidiary that remains uncollected.
Key Highlights
Acquisition of 52% stake in Inqube Technologies for ₹30.16 crores to be completed in tranches over 24 months.
Standalone Q3 FY26 revenue reported at ₹7,363.09 lakhs with a net profit of ₹217.10 lakhs.
Capitalized ₹2,244.57 lakhs following the operationalization of packaging units at the Haldia Manufacturing facility.
Auditors flagged a delay in receiving ₹605.07 lakhs dividend income from foreign subsidiary Hal Exim Pte Limited.
Strategic entry into carbon credit commercialization and tech-driven agricultural value chain efficiency.
💼 Action for Investors
Investors should monitor the successful integration of Inqube's tech platform and the timely repatriation of the ₹6.05 crore dividend from the foreign subsidiary. The operationalization of the Haldia unit is a positive sign for future production capacity.
Halder Venture Q3 Net Profit Jumps 105% YoY to ₹2.17 Cr; Announces 52% Stake Buy in InQube
Halder Venture reported a robust performance for Q3 FY26, with standalone revenue growing 28.8% YoY to ₹73.63 crore and net profit doubling to ₹2.17 crore. The company is aggressively expanding, having operationalized its Haldia Manufacturing Unit and announcing a ₹30.16 crore acquisition of a 52% stake in InQube Technologies to enter the Agri-ERP and carbon credit markets. However, investors should monitor an auditor's emphasis regarding a delayed ₹6.05 crore dividend from a foreign subsidiary. For the nine-month period, net profit stands significantly higher at ₹13.45 crore compared to ₹7.15 crore in the previous year.
Key Highlights
Standalone Net Profit for Q3 FY26 surged 105% YoY to ₹217.10 lakhs from ₹105.76 lakhs.
Revenue from operations increased by 28.8% YoY to ₹7,363.09 lakhs compared to ₹5,716.92 lakhs.
Approved acquisition of 52% stake in InQube Technologies for ₹3,016 lakhs to enter Agri-ERP and carbon credit sectors.
Capitalized ₹2,244.57 lakhs for packaging operations at the Haldia Manufacturing Unit during the quarter.
Auditor raised an emphasis of matter regarding ₹605.07 lakhs in delayed dividend income from a foreign subsidiary.
💼 Action for Investors
The strong earnings growth and strategic diversification into agri-tech are positive indicators, but investors should seek clarity on the recoverability of the ₹6.05 crore foreign dividend highlighted by auditors.